180 Life Sciences engages Kinexum to support MAA submission for adalimumab

80 Life Sciences announced that the Company has engaged Kinexum, a strategic advisory firm, to support the Company in submitting a Marketing Authorisation Application for adalimumab to treat progressive early-stage Dupuytren’s disease. The MAA will be submitted to the United Kingdom’s Medicines and Healthcare products Regulatory Agency. As part of the application, the Company expects to request a Conditional Marketing Authorisation, which assures the Agency that long term outcome data will be forthcoming. Including the costs associated with the Kinexum agreement, the Company anticipates that it will spend, in aggregate, approximately $900,000 to $1,000,000 in the next three quarters for activities associated with the MHRA filing and other regulatory preparations.